9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Estimated reading time: < 1 min

Condition: Advanced Solid Tumors (Part A/B/C/D)

Estimated Enrollment: 220

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Part A/B/C: Dose Limiting Toxicities (DLT),  Part D/E: Adverse Events (AE) and safety laboratory values,  Part A/B: Adverse Events (AE) and safety laboratory values, Part A/B: Plasma concentrations of IPI-549 (metabolites, as appropriate)

Interventions: IPI-549, Nivolumab

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: October 2019

Completion Date: April 2020

Last  Posted Date: July 29, 2019

Location: UCSD, San Diego, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02637531

Was this article helpful?
Dislike 0